<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>IL-13 Inhibition &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/il-13-inhibition/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 11 Dec 2025 18:03:36 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>IL-13 Inhibition &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Lebrikizumab’s Impact on Itch Relief: A Review</title>
		<link>https://bioengineer.org/lebrikizumabs-impact-on-itch-relief-a-review/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 11 Dec 2025 18:03:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[IL-13 Inhibition]]></category>
		<category><![CDATA[Lebrikizumab]]></category>
		<category><![CDATA[Monoclonal Antibody Therapy]]></category>
		<category><![CDATA[Pruritus Treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/lebrikizumabs-impact-on-itch-relief-a-review/</guid>

					<description><![CDATA[A recent narrative review by renowned dermatologists Yosipovitch, Kim, and Ständer has drawn significant attention within the medical community for its comprehensive evaluation of Lebrikizumab, a monoclonal antibody, and its efficacy against pruritus. Pruritus, or severe itching, is a perplexing symptom often associated with various dermatological conditions, including eczema, psoriasis, and other inflammatory disorders. This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">306139</post-id>	</item>
	</channel>
</rss>
